Subtopic Deep Dive

Antigen Cross-Presentation
Research Guide

What is Antigen Cross-Presentation?

Antigen cross-presentation is the process by which dendritic cells process exogenous antigens for MHC class I presentation to CD8 T cells, enabling cytotoxic T cell responses against viruses and tumors.

Dendritic cells capture extracellular antigens, route them to the cytosol for proteasomal degradation, and load peptides onto MHC class I via TAP transporters (Banchereau and Steinman, 1998; 14241 citations). This pathway contrasts with classical MHC class I presentation of endogenous antigens. Over 10 key papers from 1994-2018 detail DC roles, with Banchereau et al. (2000; 6583 citations) highlighting DC antigen capture.

Curated Papers

Key Challenges

Why It Matters

Cross-presentation drives CD8 T cell priming essential for anti-tumor vaccines like sipuleucel-T, which extended survival in prostate cancer patients (Kantoff et al., 2010; 5404 citations). It underpins immunotherapy efficacy against breast cancer via PD-1/PD-L1 blockade (Hartkopf et al., 2016; 30894 citations). DCs control immunity through cross-presentation, influencing tumor microenvironments (Binnewies et al., 2018; 5583 citations) and vaccine design.

Key Research Challenges

Endosomal Escape Mechanisms

Exogenous antigens must escape endosomes to access cytosol for cross-presentation, but pathways remain incompletely defined. Banchereau and Steinman (1998) describe DC antigen processing, yet efficiency varies by antigen type. Sallusto and Lanzavecchia (1994; 5116 citations) show GM-CSF/IL-4 maintains DC capacity, highlighting cytokine dependencies.

Adjuvant Enhancement Limits

Adjuvants like TLR ligands boost cross-presentation but risk excessive inflammation. Hemmi et al. (2000; 6361 citations) identify TLR9 recognizing bacterial DNA to activate DCs. Balancing activation without tolerance induction, as in IL-10 effects (Moore et al., 2001; 6619 citations), poses ongoing issues.

Tumor Microenvironment Suppression

Tumor-associated factors impair DC cross-presentation in vivo. Binnewies et al. (2018) map TIME components suppressing immunity. Mantovani et al. (2002; 5416 citations) detail M2 macrophage polarization inhibiting DCs.

Essential Papers

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · 2016 · Breast Care · 30.9K citations

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, P...

Dendritic cells and the control of immunity

Jacques Banchereau, Ralph M. Steinman · 1998 · Nature · 14.2K citations

Interleukin-10 and the Interleukin-10 Receptor

Kevin W. Moore, René de Waal Malefyt, Robert L. Coffman et al. · 2001 · Annual Review of Immunology · 6.6K citations

Interleukin-10 (IL-10), first recognized for its ability to inhibit activation and effector function of T cells, monocytes, and macrophages, is a multifunctional cytokine with diverse effects on mo...

Immunobiology of Dendritic Cells

Jacques Banchereau, Francine Brière, Christophe Caux et al. · 2000 · Annual Review of Immunology · 6.6K citations

Dendritic cells (DCs) are antigen-presenting cells with a unique ability to induce primary immune responses. DCs capture and transfer information from the outside world to the cells of the adaptive...

A Toll-like receptor recognizes bacterial DNA

Hiroaki Hemmi, Osamu Takeuchi, Taro Kawai et al. · 2000 · Nature · 6.4K citations

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Federica Sallusto, Danielle Lenig, Reinhold Förster et al. · 1999 · Nature · 5.7K citations

Understanding the tumor immune microenvironment (TIME) for effective therapy

Mikhail Binnewies, Edward W. Roberts, Kelly Kersten et al. · 2018 · Nature Medicine · 5.6K citations

Reading Guide

Foundational Papers

Start with Banchereau and Steinman (1998; 14241 citations) for DC immunity control, then Banchereau et al. (2000; 6583 citations) for antigen capture details, and Sallusto and Lanzavecchia (1994; 5116 citations) for culture methods.

Recent Advances

Study Binnewies et al. (2018; 5583 citations) on TIME and Hartkopf et al. (2016; 30894 citations) on PD-1 blockade linking to cross-presentation applications.

Core Methods

Core techniques include GM-CSF/IL-4 DC generation (Sallusto 1994), TLR stimulation (Hemmi 2000), and cytosolic routing assays via TAP dependence (Banchereau 2000).

How PapersFlow Helps You Research Antigen Cross-Presentation

Discover & Search

Research Agent uses searchPapers and citationGraph on 'antigen cross-presentation dendritic cells' to map 250M+ OpenAlex papers, centering Banchereau and Steinman (1998; 14241 citations) with 50+ citing works on DC immunity. exaSearch finds niche reviews; findSimilarPapers expands to Sallusto and Lanzavecchia (1994).

Analyze & Verify

Analysis Agent applies readPaperContent to extract cross-presentation mechanisms from Banchereau et al. (2000), then verifyResponse with CoVe chain-of-verification flags contradictions in cytokine effects. runPythonAnalysis processes citation networks with pandas for DC paper clusters; GRADE grades evidence strength for TAP transport claims.

Synthesize & Write

Synthesis Agent detects gaps in adjuvant-DC studies via contradiction flagging across Hemmi et al. (2000) and Moore et al. (2001). Writing Agent uses latexEditText, latexSyncCitations for figure legends on MHC pathways, and latexCompile for immunotherapy reviews; exportMermaid diagrams endosomal escape routes.

Use Cases

"Analyze citation trends in DC cross-presentation papers using Python."

Research Agent → searchPapers('cross-presentation dendritic') → Analysis Agent → runPythonAnalysis(pandas plot citations over time) → matplotlib trend graph showing Banchereau 1998 peak.

"Draft LaTeX review on cross-presentation in tumor vaccines."

Synthesis Agent → gap detection on Kantoff 2010 → Writing Agent → latexEditText(manuscript) → latexSyncCitations(Banchereau papers) → latexCompile → PDF with synced refs and sipuleucel-T figure.

"Find GitHub code for DC antigen processing simulations."

Research Agent → citationGraph(Banchereau 2000) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Jupyter notebooks modeling TAP transport kinetics.

Automated Workflows

Deep Research workflow scans 50+ DC papers via searchPapers → citationGraph → structured report on cross-presentation evolution from Sallusto 1994 to Binnewies 2018. DeepScan's 7-step analysis with CoVe verifies IL-10 suppression (Moore 2001) across abstracts. Theorizer generates hypotheses on TLR adjuvants from Hemmi 2000 data chains.

Try Doxa for Antigen Cross-Presentation Research

Frequently Asked Questions

What defines antigen cross-presentation?

It is dendritic cells processing exogenous antigens for MHC class I to prime CD8 T cells (Banchereau and Steinman, 1998).

What methods enhance cross-presentation?

GM-CSF plus IL-4 culture maintains DC efficiency (Sallusto and Lanzavecchia, 1994); TLR ligands like bacterial DNA activate via TLR9 (Hemmi et al., 2000).

What are key papers?

Banchereau and Steinman (1998; 14241 citations) on DC immunity; Banchereau et al. (2000; 6583 citations) on DC immunobiology; Kantoff et al. (2010; 5404 citations) on DC vaccines.